Comparing the current results to its competitors, Beam Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -94.21 %, despite the revenue increase by the most of its competitors of 17.73 %, recorded in the same quarter.
November 5, 2024
Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, recently made significant presentations at the American Society of Hematology (ASH) Annual Meeting. The data presented encapsulates crucial insights from their hematology franchise, particularly highlighting the first clinical data from the BEAM-101 trial in sickle cell disease. Despite the promising clinical advances, Beam Therapeutics experienced notable economic hurdles in the second quarter of 2024. Clinical Advances in Sickle Cell DiseaseAt the ASH Annual Meeting, Beam Therapeutics presen...
March 26, 2024
Beam Therapeutics Announces Clearance of Clinical Trial Authorization Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Beam Therapeutics, a leading biotechnology company, has recently announced the clearance of its clinical trial authorization application for BEAM-302, a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD). This milestone brings new hope for patients suffering from this rare genetic disorder. AATD is characterized by a deficiency of the Alpha-1 Antitrypsin protein, leading to lung and liver diseases.The clearance of the clinical trial authorization application signifies an essential step towards conducting human trials to evaluate the safety and eff...
Prime Medicine Inc is a biotechnology company specializing in gene editing technologies and therapeutics. Their business model revolves around harnessing advanced CRISPR-based gene editing techniques to develop treatments for genetic diseases. By using innovative science and strategic partnerships, the company aims to bring transformative therapies to patients in need.
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
Biontech SE's business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.
Precision Biosciences Inc operates under a business model focused on gene editing. They develop and commercialize its ARCUS genome editing platform to create innovative therapies for genetic diseases and cancer. The company offers its gene editing capabilities to partners and collaborates on various research and development projects.
Sources:
Beam Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Beam Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
